Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope 
Define a set of best practices for data transparency and create a Good Transparency Practices guidance. The best practices will aim to ensure anonymised data is compliant with the legal requirements as defined by Regulators, as well as preserves as much data utility as possible. If possible, Regulators such as the European Medicines Agency (EMA) and Health Canada will be consulted to ensure that the guidance created by the working group reflects their current standards. The planned document will have a similar format as the Good Clinical Practices guidance created by the International Conference on Harmonisation (ICH). The Good Transparency Practices document will include: an introduction, a glossary of terms, a set of principles, and subsections dedicated to different parties involved in the anonymisation process (such as the trial sponsor and the entity performing the anonymisation) describing their responsibilities and providing guidance. Additional sections may be added as needed.   


Project Statement 
Transparency initiatives allow public scrutiny and research in the application of new knowledge based on clinical data. Current GxP guidelines do not apply to transparency as it represents a different flow of data in which anonymisation is carried out on a copy of the regulated data.


Project Impact
Good Transparency Practices (GTP) would provide a means to achieving accountability and traceability while providing reasonable assurance that privacy requirements are being upheld.



Project LeadsEmail

Lauren Hepburn (Iconic)

lauren.hepburn@iconplc.com

Abby McDonell (Privacy Analytics)

amcdonell@privacy-analytics.com

Paula Rowley (PHUSE Project Assistant)paula@phuse.global 


Objectives & Deliverables Timelines
Good Transparency Practices guidance documentQ3 2022


Status
colourBlue
titleCurrent Status
Q2Q3/3 4 2022

  • Group are completing current background research and organising notes to prepare for writing the GTP guidance.
  • Successfully solicited involvement from the EMA and Health Canada.
  • Group are beginning the first draft of GTP guidance.



Project MembersOrganisation
Abhinav SrivastvaExelixis
Andre MolgatHealth Canada 
Benjamin C ShimEli Lilly
Brenda TiffinClaritidox
Cara CamporaBeigene
Devaki ThavarajahIndustry
Dhiraj DabhiEli Lilly
Mahesh SwaminathanBristol Myers Squibb
Manohara Basoor HalasiddappaAlgok Bio
Mekhala AcharyaTakeda
Sanjay Bagani Xogene 
Sarah BalayPrivacy Analytics
Sharon NiedeckenPfizer
Shannon LefaivreRoche
Shweta SrivastavaXogene 
Sophia ZilberPfizer
Rama EmpatiAstrazeneca